Eli Lilly Proposes Discount on Mounjaro Price Hike

London, August 29, 2025 - Eli Lilly, manufacturer of the weight-loss drug Mounjaro (tirzepatide), today announced a proposed discount on its planned UK price increase, offering the highest 15 mg monthly dose at £247.50 instead of the originally scheduled £330. Despite the reduction, this represents more than a 100% rise from the current £122 monthly list price.

The decision follows pressure from former US President Donald Trump, who earlier this year urged American drugmakers to raise prices abroad to enable lower US costs. In response to an outcry from UK patients-many of whom began stockpiling doses amid fears of shortages-Eli Lilly suspended sales to wholesalers in late August. Under the new proposal, private providers are expected to pass on the £82.50-per-month rebate to patients when the price change takes effect on September 1.

Pharmacies and private weight-loss clinics set their own charges, meaning the final cost to end users may still vary. Eli Lilly emphasized that access via the National Health Service, where Mounjaro was rolled out in June, will remain unaffected by the price adjustment. The company is working “with private providers to maintain affordability” and will monitor supply allocations to prevent inappropriate stockpiling.